NasdaqGS - Delayed Quote USD

Sinovac Biotech Ltd. (SVA)

6.47

0.00

(0.00%)

At close: January 16 at 4:00:00 PM EST

SINOVAC Issues Statement Regarding Privy Council Judgment

BEIJING, January 16, 2025--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company’s Rights Agreement is invalid. The ruling will take effect after e

Business Wire 10 days ago

SVA
0.00%
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

BEIJING, December 16, 2024--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marketing worldwide.

Business Wire last month

SVA
0.00%
SINOVAC Reports Unaudited First Half of 2024 Financial Results

BEIJING, August 16, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2024.

Business Wire 5 months ago

SVA
0.00%
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

BEIJING, April 29, 2024--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual report can be accessed on the Company's investor relations website at http://www.sinovac.com/en-us/Investors. The Company also reported its unaudited financial results for the second half and audited financi

Business Wire 8 months ago

SVA
0.00%
Sinovac Amends Shareholder Rights Plan

BEIJING, February 21, 2024--Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

Business Wire 10 months ago

SVA
0.00%

Performance Overview

Return	SVA	S&P 500
YTD	0.00%	+3.29%
1-Year	0.00%	+25.42%
3-Year	0.00%	+38.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sinovac Biotech Ltd. (SVA)

SINOVAC Issues Statement Regarding Privy Council Judgment

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

SINOVAC Reports Unaudited First Half of 2024 Financial Results

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Sinovac Amends Shareholder Rights Plan

Performance Overview